Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up

Fertility and Sterility
G S LetterieR L Collins

Abstract

The authors employed a gonadotropin-releasing hormone agonist (GnRH-a) (D-His6-pro9-NET-GnRH) to treat 19 patients with symptomatic uterine leiomyomata, by daily subcutaneous injections (4 micrograms/kg) for 6 months. After therapy, patients were followed for 6 months without any therapy. Uterine volumes were measured by serial pelvic examinations and pelvic sonography. Measurements of serum estradiol, luteinizing hormone, and follicle-stimulating hormone were used to assess treatment response. Pituitary desensitization and hypoestrogenemia were achieved in all within 8 weeks, and in 18 of 19, hypoestrogenemia was maintained for the duration. Uterine volume at the conclusion of therapy (207.5 +/- 152.7 ml) was significantly reduced in all patients when compared with pretreatment sizes (420.8 +/- 276.4, P less than 0.05). Side effects included hot flashes (78%), vaginal dryness (32%), and transient frontal headaches (55%). All patients reported partial or complete relief from their symptomatic leiomyomata. Uterine volume at the conclusion of follow-up (345.4 +/- 195.7 ml) was greater than at the conclusion of therapy. Menses resumed in all patients within 4 to 8 weeks. In conclusion, GnRH-a therapy does not provide definitive th...Continue Reading

Citations

May 10, 1991·European Journal of Obstetrics, Gynecology, and Reproductive Biology·A VolpeA R Genazzani
Jul 25, 1991·European Journal of Obstetrics, Gynecology, and Reproductive Biology·A M FranssenR Rolland
Jun 1, 1996·European Journal of Obstetrics, Gynecology, and Reproductive Biology·O JourdainG Body
Aug 1, 1993·American Journal of Reproductive Immunology : AJRI·L V RaoK M Ataya
Apr 1, 1996·The American Journal of Surgical Pathology·J J SreenanW R Hart
May 10, 2001·Clinical Obstetrics and Gynecology·G M Christman, J D McCarthy
Nov 1, 1991·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·M A ThomasJ H Liu
Apr 1, 1990·British Journal of Obstetrics and Gynaecology·B J VollenhovenD L Healy
Sep 1, 1992·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·H A van Leusden
Jun 20, 2002·Clinical Endocrinology·L A KieselA Szilágyi
Feb 1, 1992·British Journal of Obstetrics and Gynaecology·G BenagianoF M Primiero
May 1, 1992·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·B Acar, C Posaci
Sep 4, 2007·Obstetrics and Gynecology·Fotios K VarelasGeorgios D Vlassis
Jun 1, 1991·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·K BiberogluA Yildiz
Feb 1, 1992·British Journal of Obstetrics and Gynaecology·D L Healy, B J Vollenhoven
Jun 1, 1994·Postgraduate Medicine·Craig A Winkel
Apr 18, 1998·The Journal of the American Association of Gynecologic Laparoscopists·T G ZreikD L Olive
Feb 19, 1999·Baillière's Clinical Obstetrics and Gynaecology·M A Lumsden, E M Wallace
Jul 31, 2007·Fertility and Sterility·William H Parker

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.